B·R·A·H·M·S Aktiengesellschaft Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a BRAHMS Aktiengesellschaft's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reason to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Contents

• 1 Table of Contents
  • 1.1 List of Tables
  • 1.2 List of Figures
• 2 Company Overview
  • 2.1 Key Information
  • 2.2 Financial Performance
  • 2.3 Industry Outlook - In Vitro Diagnostics
• 3 BRAHMS Aktiengesellschaft Pipeline Products
  • 3.1 BRAHMS Aktiengesellschaft Product Pipeline Analysis
    • 3.1.1 BRAHMS Aktiengesellschaft Pipeline Products By Equipment Type
    • 3.1.2 BRAHMS Aktiengesellschaft Pipeline Products By Development Stage
    • 3.1.3 BRAHMS Aktiengesellschaft Pipeline Products By Therapy Area
    • 3.1.4 BRAHMS Aktiengesellschaft Pipeline Products By Clinical Trials
  • 3.2 BRAHMS TRAK KRYPTOR
    • 3.2.1 Product Description
    • 3.2.2 Product Status
  • 3.3 MR-proANP biomarker
    • 3.3.1 Product Description
    • 3.3.2 Product Status
  • 3.4 MR-proADM biomarker
    • 3.4.1 Product Description
    • 3.4.2 Product Status
    • 3.4.3 Clinical Trials
  • 3.5 CT-proAVP biomarker
    • 3.5.1 Product Description
    • 3.5.2 Product Status
  • 3.6 CT-proET-1 biomarker
    • 3.6.1 Product Description
    • 3.6.2 Product Status
    • 3.6.3 Clinical Trials
• 4 Major Products and Services
  • 4.1 Overview
• 5 Competitors
• 6 Key Employees
• 7 Locations And Subsidiaries
  • 7.1 Head Office
  • 7.2 Other Locations & Subsidiaries
• 8 Appendix
  • 8.1 Methodology
    • 8.1.1 Coverage
    • 8.1.2 Secondary Research
    • 8.1.3 Primary Research
    • 8.1.4 Expert Panel Validation
  • 8.2 Contact Us
  • 8.3 About Global Markets Direct
  • 8.4 Disclaimer
• List of Tables
  • Table 1: BRAHMS Aktiengesellschaft,Key Facts
  • Table 2: BRAHMS Aktiengesellschaft Pipeline Products by Equipment Type
  • Table 3: BRAHMS Aktiengesellschaft Pipeline Products By Development Stage
  • Table 4: BRAHMS Aktiengesellschaft Pipeline Products By Therapy Area
  • Table 5: BRAHMS Aktiengesellschaft Pipeline Products By Clinical Trials
  • Table 6: BRAHMS Aktiengesellschaft, Key Employees,
  • Table 7: BRAHMS Aktiengesellschaft, Other Locations
  • Table 8: BRAHMS Aktiengesellschaft, Subsidiaries
• List of Figures
  • Figure 1: Global Markets Direct Methodology